NextCure (NASDAQ:NXTC) Given New $4.00 Price Target at HC Wainwright

NextCure (NASDAQ:NXTC) had its price objective cut by research analysts at HC Wainwright from $8.00 to $4.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 159.74% from the company’s current price.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 target price on shares of NextCure in a report on Friday, August 2nd.

NextCure Stock Up 13.2 %

Shares of NASDAQ NXTC opened at $1.54 on Monday. The business has a 50-day simple moving average of $1.37 and a two-hundred day simple moving average of $1.49. NextCure has a 52 week low of $1.03 and a 52 week high of $2.57. The company has a market cap of $43.08 million, a P/E ratio of -0.65 and a beta of 0.80.

Institutional Trading of NextCure

A number of large investors have recently modified their holdings of the business. Armistice Capital LLC bought a new position in shares of NextCure in the second quarter worth approximately $57,000. Renaissance Technologies LLC raised its position in shares of NextCure by 15.4% during the 2nd quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock valued at $735,000 after buying an additional 61,744 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of NextCure by 9.3% during the 1st quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock worth $2,202,000 after acquiring an additional 83,700 shares during the last quarter. Affinity Asset Advisors LLC purchased a new position in NextCure in the first quarter worth $3,031,000. Finally, Logos Global Management LP increased its stake in NextCure by 29.9% in the second quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock valued at $3,975,000 after acquiring an additional 575,000 shares during the last quarter. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.